Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura W Dillon

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Science Advances|July 9, 2025
Single-cell spatial transcriptomics reveals immunotherapy-driven bone marrow niche remodeling in AMLGege Gui, Molly A Bingham, Julius R Herzog, et al.
Frontiers in Oncology|January 31, 2019
Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical ResponseHong Yuen Wong, Anthony D Sung, Katherine E Lindblad, et al.
Blood Advances|January 28, 2020
Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemiaHaydar Çelik, Katherine E Lindblad, Bogdan Popescu, et al.
Blood|June 4, 2026
ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid LeukemiaChristopher S Hourigan, Lisanne Beugelink, Jad Othman, et al.
JAMA|March 7, 2023
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell TransplantLaura W Dillon, Gege Gui, Kristin M Page, et al.
Bone Marrow Transplantation|October 18, 2024
Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemiaPranay S Hegde, Georgia Andrew, Gege Gui, et al.
Medrxiv : the Preprint Server for Health Sciences|August 14, 2023
Measurable Residual <i>IDH1</i> before Allogeneic Transplant for Acute Myeloid LeukemiaGege Gui, Laura W Dillon, Niveditha Ravindra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2019
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual DiseaseChristopher S Hourigan, Laura W Dillon, Gege Gui, et al.
JCO Precision Oncology|May 26, 2021
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic SyndromeLaura W Dillon, Gege Gui, Brent R Logan, et al.
Journal for Immunotherapy of Cancer|January 12, 2022
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemiaMeghali Goswami, Gege Gui, Laura W Dillon, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Science Advances|July 9, 2025
Single-cell spatial transcriptomics reveals immunotherapy-driven bone marrow niche remodeling in AMLGege Gui, Molly A Bingham, Julius R Herzog, et al.
Frontiers in Oncology|January 31, 2019
Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical ResponseHong Yuen Wong, Anthony D Sung, Katherine E Lindblad, et al.
Blood Advances|January 28, 2020
Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemiaHaydar Çelik, Katherine E Lindblad, Bogdan Popescu, et al.
Blood|June 4, 2026
ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid LeukemiaChristopher S Hourigan, Lisanne Beugelink, Jad Othman, et al.
JAMA|March 7, 2023
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell TransplantLaura W Dillon, Gege Gui, Kristin M Page, et al.
Bone Marrow Transplantation|October 18, 2024
Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemiaPranay S Hegde, Georgia Andrew, Gege Gui, et al.
Medrxiv : the Preprint Server for Health Sciences|August 14, 2023
Measurable Residual <i>IDH1</i> before Allogeneic Transplant for Acute Myeloid LeukemiaGege Gui, Laura W Dillon, Niveditha Ravindra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2019
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual DiseaseChristopher S Hourigan, Laura W Dillon, Gege Gui, et al.
JCO Precision Oncology|May 26, 2021
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic SyndromeLaura W Dillon, Gege Gui, Brent R Logan, et al.
Journal for Immunotherapy of Cancer|January 12, 2022
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemiaMeghali Goswami, Gege Gui, Laura W Dillon, et al.
Pageof 5